Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
MA39836AUndetermined Publication Date: 2017-03-08TEVA PHARMA AUSTRALIA PTY LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA39836
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-05-01
- Filing Date
- 2015-05-01
- Publication Date
- 2017-03-08
Abstract
Methods for cancer treatment include administering to a cancer patient an anti- cd38 antibody-attenuated human ifn alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise cd-38 expressing tumor cells, including b-cell lymphoma, multiple myeloma, non-hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Need to check novelty before this filing date? Find Prior Art